NurseKim_ATL said:Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…
This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.
PeptideSynthNJ said:dan_philly said: ...we're creating a generation dependent on cardiovascular risk...
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 52" → 34" ✅ Resolved
- Triglycerides: 260 → 100 ✅ Resolved
- HDL: 36 → 52 ✅ Resolved
- Blood pressure: 140/90 → 118/72 ✅ Resolved
- Fasting glucose: 125 → 88 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.
A narrower follow-up, since the general answer is now clear:
How long did you give it before you decided it was working?
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultslucas_SP_BR said:Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely! My cardiologist is thrilled.
If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.